Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease

References

• Meng J, Stobart CC, Hotard AL, Moore ML. An overview of respiratory syncytial virus. PLoS Pathog. 2014;10(4):e1004016.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–2064. doi:10.1016/S0140-6736(22)00478-0
   PubMed Web of Science ®Google Scholar
• Haber N. Respiratory syncytial virus infection in elderly adults. Med Mal Infect. 2018;48(6):377–382. doi:10.1016/j.medmal.2018.01.008
   PubMed Web of Science ®Google Scholar
• Anderson J, Oeum M, Verkolf E, et al. Factors associated with severe respiratory syncytial virus disease in hospitalised children: a retrospective analysis. Arch Dis Child. 2021;107:359–364. doi:10.1136/archdischild-2021-322435
   PubMed Web of Science ®Google Scholar
• Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis—a prospective birth-cohort study. Pediatrics. 2007;120:e1076–e1081. doi:10.1542/peds.2007-0788
   PubMed Web of Science ®Google Scholar
• Murray J, Bottle A, Sharland M, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One. 2014;9:e89186. doi:10.1371/journal.pone.0089186
   PubMed Web of Science ®Google Scholar
• Kristensen K, Hjuler T, Ravn H, Simões EA, Stensballe LG. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis. 2012;54:810–817. doi:10.1093/cid/cir928
   PubMed Web of Science ®Google Scholar
• Igueras-Aloy J, Manzoni P, Paes B, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016;5(4):417–452. doi:10.1007/s40121-016-0130-1
   PubMedGoogle Scholar
• Haerskjold A, Kristensen K, Kamper-Jorgensen M, Nybo Andersen AM, Ravn H, Graff Stensballe L. Risk factors for hospitalization for respiratory syncytial virus infection: a population-based cohort study of Danish children. Pediatr Infect Dis J. 2016;35(1):61–65. doi:10.1097/INF.0000000000000924
   PubMed Web of Science ®Google Scholar
• Nguyen-van-tam J, Wyffels V, Smulders M, et al. Cumulative incidence of post-infection asthma or wheezing among young children clinically diagnosed with respiratory syncytial virus infection in the United States: a retrospective database analysis. Influenza Other Respir Viruses. 2020;14:730–738. doi:10.1111/irv.12770
   PubMed Web of Science ®Google Scholar
• Driscoll AJ, Arshad SH, Bont L, et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine. 2020;38(11):2435–2448. doi:10.1016/j.vaccine.2020.01.020
   PubMed Web of Science ®Google Scholar
• Esteban I, Stein RT, Polack FP. A durable relationship: respiratory syncytial virus bronchiolitis and asthma past their golden anniversary. Vaccines. 2020;8(2):201. doi:10.3390/vaccines8020201
   Web of Science ®Google Scholar
• Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi:10.1016/S0140-6736(17)30938-8
   PubMed Web of Science ®Google Scholar
• Zhang S, Akmar LZ, Bailey F, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: a systematic review and meta-analysis. J Infect Dis. 2020;222(7):680–687. doi:10.1093/infdis/jiz683
   Google Scholar
• Bozzola E, Ciarlitto C, Guolo S, et al. Respiratory syncytial virus bronchiolitis in infancy: the acute hospitalization cost. Front Pediatr. 2021;8:594898. doi:10.3389/fped.2020.594898
   PubMed Web of Science ®Google Scholar
• Brusco NK, Alafaci A, Tuckerman J, et al. The 2018 annual cost burden for children under five years of age hospitalised with respiratory syncytial virus in Australia. Commun Dis Intell. 2018;2022:46.
   Google Scholar
• Messina A, Germano C, Avellis V, et al. New strategies for the prevention of respiratory syncytial virus (RSV). Early Hum Dev. 2022;174:105666. doi:10.1016/j.earlhumdev.2022.105666
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 March 2015. Vaccine. 2016;34(2):190–197. doi:10.1016/j.vaccine.2015.05.093
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration. FDA news release, FDA approves first Respiratory Syncytial Virus (RSV) vaccine, arexvy approved for individuals 60 years of age and older; 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine. Accessed June 22, 2023.
   Google Scholar
• European Medicines Agency. First RSV vaccine to protect infants up to 6 months of age and older adults; 2023. Available from: https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-older-adults. Accessed August 1, 2023.
   Google Scholar
• Pfizer. Pfizer press release, U.S. FDA approves ABRYSVO™, Pfizer’s vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults; 2023. Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention. Accessed August 1, 2023.
   Google Scholar
• Johnson EM. The effects of ribavirin on development and reproduction: a critical review of published and unpublished studies. Endocrinology. 1990;131:1149–1156.
   Google Scholar
• Kilham L, Ferm VH. Congenital anomalies induced in hamster embryos with ribavirin. Science. 1977;195(4276):413–414. doi:10.1126/science.401547
   PubMed Web of Science ®Google Scholar
• Ferm VH, Willhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology. 1978;17(1):93–102. doi:10.1002/tera.1420170117
   PubMedGoogle Scholar
• Linn WS, Gong H Jr, Anderson KR, Clark KW, Shamoo DA. Exposures of health-care workers to ribavirin aerosol: a pharmacokinetic study. Arch Environ Health. 1995;50(6):445–451. doi:10.1080/00039896.1995.9935981
   PubMed Web of Science ®Google Scholar
• Rodriguez WJ, Bui RH, Connor JD. Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Antimicrob Agents Chemother. 1987;31(7):1143–1146. doi:10.1128/AAC.31.7.1143
   PubMed Web of Science ®Google Scholar
• Bortolussi RA, Gold R. Ribavirin aerosol therapy: safety for staff. Can Med Assoc J. 1988;138:204.
   Web of Science ®Google Scholar
• Smith DW, Frankel LR, Mathers LH, Tan ATS, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325(1):24–29. doi:10.1056/NEJM199107043250105
   PubMed Web of Science ®Google Scholar
• Moler FW, Bandy KP, Custer JR. Ribavirin therapy for acute bronchiolitis: need for appropriate controls. J Pediatr. 1991;119(3):509–510. doi:10.1016/S0022-3476(05)82091-8
   PubMed Web of Science ®Google Scholar
• Tejada S, Martinez-Reviejo R, Karakoc HN, Peña-López Y, Manuel O, Rello J. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis. Adv Ther. 2022;39(9):4037–4051. doi:10.1007/s12325-022-02256-5
   PubMed Web of Science ®Google Scholar
• Anak S, Atay D, Unuvar A, et al. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatr Pulmonol. 2010;45(3):307–311. doi:10.1002/ppul.21184
   PubMed Web of Science ®Google Scholar
• Smyth RL, Brearey SP. Bronchiolitis. In: Laurent GJ, Shapiro SD, editors. Encyclopedia of Respiratory Medicine. Academic Press; 2006:268–275.
   Google Scholar
• Stiehm RE, Keller MA. Chapter 256 – passive Immunisation. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, editors. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. 6th ed. Amazon; 2009:3401–3446.
   Google Scholar
• The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93–99. doi:10.1542/peds.99.1.93
   PubMed Web of Science ®Google Scholar
• Junge S, Nokes DJ, Simões EAF, Weber MW. Respiratory syncytial virus. In: Stella R, editor. Quah. International Encyclopedia of Public Health. 2nd ed. Academic Press; 2017:337–346.
   Google Scholar
• Simoes EA, Sondheimer HM, Top FH, et al.; The Cardiac Study Group. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr. 1998;133:492–499.
   PubMed Web of Science ®Google Scholar
• Oertel MD. RespiGam: an RSV immune globulin. Pediatr Nurs. 1996;22(6):525.
   PubMedGoogle Scholar
• Simões EAF, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7(1):87–120. doi:10.1007/s40121-018-0188-z
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–537. doi:10.1542/peds.102.3.531
   Web of Science ®Google Scholar
• Public Health England. Chapter 27a: respiratory Syncytial Virus. In: Immunisation Against Infectious Disease (Green Book). London: Department of Health; 2015.
   Google Scholar
• Harkensee C, Brodlie M, Embleton ND, Mckean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect. 2006;52(1):2–8. doi:10.1016/j.jinf.2005.08.003
   PubMed Web of Science ®Google Scholar
• Paediatric Formulary Committee. BNF for Children. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2022.
   Google Scholar
• Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JVA. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021;11(11):CD013757. doi:10.1002/14651858.CD013757.pub2
   PubMedGoogle Scholar
• Sun M, Lai H, Na F, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023;6(2):e230023. doi:10.1001/jamanetworkopen.2023.0023
   PubMed Web of Science ®Google Scholar
• Gonzales T, Bergamasco A, Cristarella T, et al. Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: a systematic review. Am J Perinatol. 2023. doi:10.1055/a-1990-2633
   PubMed Web of Science ®Google Scholar
• Manzoni P, Baraldi E, Luna MS, Tzialla C. Real-world studies of respiratory syncytial virus hospitalizations among moderate/late preterm infants exposed to passive immunoprophylaxis with palivizumab. Am J Perinatol. 2022;39(1):7–13. doi:10.1055/s-0042-1757279
   Google Scholar
• Priante E, Tavella E, Girardi E, et al. Restricted palivizumab recommendations and the impact on RSV hospitalizations among infants born at > 29 weeks of gestational age: an Italian multicenter study. Am J Perinatol. 2019;36(2):77–82. doi:10.1055/s-0039-1691771
   Google Scholar
• Paes B, Mitchell I, Li A, Lanctôt KL. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis. 2012;31(10):2703–2711. doi:10.1007/s10096-012-1617-7
   PubMed Web of Science ®Google Scholar
• Paes B, Mitchell I, Li A, Lanctôt KL. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr. 2012;171(5):833–841. doi:10.1007/s00431-011-1654-8
   PubMed Web of Science ®Google Scholar
• Resch B, Bramreiter VS, Kurath-Koller S, et al. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis. Eur J Clin Microbiol Infect Dis. 2017;36(6):1057–1062. doi:10.1007/s10096-016-2891-6
   PubMed Web of Science ®Google Scholar
• Groothuis JR. Safety of palivizumab in preterm infants 29 to 32 weeks’ gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection. Eur J Clin Microbiol Infect Dis. 2003;22(7):414–417. doi:10.1007/s10096-003-0961-z
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, et al.; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–540. doi:10.1067/S0022-3476(03)00454-2
   PubMed Web of Science ®Google Scholar
• Kua KP, Lee SWH. Systematic review of the safety and efficacy of palivizumab among infants and young children with cystic fibrosis. Pharmacotherapy. 2017;37(6):755–769. doi:10.1002/phar.1936
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kawakami K. Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series. Hum Vaccin Immunother. 2021;17(4):1235–1238. doi:10.1080/21645515.2020.1809265
   PubMed Web of Science ®Google Scholar
• Sharland M, Cant A, Dagan R, et al. Manual of Childhood Infections (Oxford Specialist Handbooks in Paediatrics): The Blue Book. 4th ed. Oxford: Oxford University Press; 2016.
   Google Scholar
• Blanken MO, Rovers MM, Molenaar JM, et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799. doi:10.1056/NEJMoa1211917
   PubMed Web of Science ®Google Scholar
• Amitai N, Stafler P, Blau H, et al. Palivizumab following extremely premature birth does not affect pulmonary outcomes in adolescents. Chest. 2020;158(2):660–669. doi:10.1016/j.chest.2020.02.075
   PubMed Web of Science ®Google Scholar
• Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011;15(5):1–124. doi:10.3310/hta15050
   Web of Science ®Google Scholar
• Wang D, Cummins C, Bayliss J, Sandercock J, Burls A. Immunoprophylaxis against RSV with palivizumab in children—a systematic review and economic evaluation. Health Technol Assess. 2008;12(36):1–86. doi:10.3310/hta12360
   Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652–665. doi:10.1016/j.jmb.2007.02.024
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15(12):398–1408.
   Web of Science ®Google Scholar
• Simões EAF, Forleo-Neto E, Geba GP, et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis. 2021;73(11):e4400–e4408. doi:10.1093/cid/ciaa951
   PubMed Web of Science ®Google Scholar
• Regeneron. Press Release: Regeneron to discontinue development of suptavumab for respiratory syncytial virus; 2017. Available from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-discontinue-development-suptavumab-respiratory. Accessed June 22, 2023.
   Google Scholar
• Domachowske JB, Khan AA, Esser MT, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis. 2018;37(9):886–892. doi:10.1097/INF.0000000000001916
   Google Scholar
• Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):1928. doi:10.1126/scitranslmed.aaj1928
   Web of Science ®Google Scholar
• Sandofi. Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants; 2022. Available from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-discontinue-development-suptavumab-respiratory. Accessed July 13, 2023.
   Google Scholar
• GOV.UK. Independent report. Respiratory Syncytial virus (RSV) immunisation programme: JCVI advice; 2023. Available from: https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023. Accessed July 13, 2023.
   Google Scholar
• Griffin MP, Yuan Y, Takas T, et al.; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–425. doi:10.1056/NEJMoa1913556
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Dagan R, Yuan Y, et al.; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837–846. doi:10.1056/NEJMoa2110275
   PubMed Web of Science ®Google Scholar
• St George’s Vaccine Institute (SGVI). Harmonie RSV Study. A Phase IIIb randomised open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus in infants (HARMONIE); 2023. Available from: https://vaccine.ac.uk/research/harmonie-study/. Accessed June 19, 2023.
   Google Scholar
• Sandofi. Press release: nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting; 2023. Available from: https://www.sanofi.com/en/media-room/press-releases/2023/2023-05-12-08-50-00-2667568. Accessed July 13, 2023.
   Google Scholar
• Tang A, Chen Z, Cox KS, et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019;10(1):4153. doi:10.1038/s41467-019-12137-1
   PubMedGoogle Scholar
• Maas BM, Lommerse J, Plock N, et al. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. eBioMedicine. 2021;73:6. doi:10.1016/j.ebiom.2021.103651
   Web of Science ®Google Scholar
• RSV vaccine and mAb snapshot; 2022. Available from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/. Accessed April 23, 2023.
   Google Scholar
• Papi A, Ison MG, Langley JM, et al; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F Protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608. doi:10.1056/NEJMoa2209604
   PubMed Web of Science ®Google Scholar
• Kampmann B, Madhi SA, Munjal I, et al.; MATISSE Study Group. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–1464. doi:10.1056/NEJMoa2216480
   PubMed Web of Science ®Google Scholar
• Boytchev H. Maternal RSV vaccine: further analysis is urged on preterm births. BMJ. 2023;381:1021. doi:10.1136/bmj.p1021
   PubMedGoogle Scholar
• GSK. GSK provides further update on Phase III RSV maternal vaccine candidate programme; 2022. Available from: www.gsk.com/en-gb/media/press-releases/gsk-provides-further-update-on-phase-iii-rsv-maternal-vaccine-candidate-programme. Accessed June 23, 2023.
   Google Scholar
• FDA. Sponsor briefing document vaccines and related biological products advisory committee meeting date: February 28-March 1, 2023. Available from: www.fda.gov/media/165621/download#page=42. Accessed June 23, 2023.
   Google Scholar